Skip to main content
Caplight Logo









20n Bio

20n Bio

Private
Malvern, PennsylvaniaHealthcare & Life Scienceshttps://www.20n.bio/

Last Round

Seed

May 20, 2026

Total Funding Raised

$10.8M

Company Overview

20n Bio is a biotechnology company that utilizes an AI-powered high-throughput screening platform to discover and develop novel cyclic peptide therapeutics for oncology and other genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

cyclic peptidedrug discoverymRNA displaypeptide therapeuticsbiotech platformhigh-throughput screeningAI drug discoveryundruggable targetspeptide-drug conjugatesradioligand therapycomputational biologyde novo designin silico discoverypharma R&Dbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

20n Bio Comparables

Compare 20n Bio with similar companies based on industry and business-model similarity.

20n Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Menten AI
83%
Dayra Therapeutics
82%
AbbVie
82%

20n Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 20, 2026
SeedDec 17, 2021

Key People

Founding team and executive leadership

Mingfu Zhu

Founder and CEO

Founding Team

20n Bio Investors

Notable investors and investment history

20n Bio investors
InvestorRounds
Lanchi VenturesSeed
Lanchi VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Web traffic grew 414% MoM (from 805 to 4.1K monthly visitors)

  • Dec 17, 2021

    $3.3M round led by Lanchi Ventures

20n Bio Filings

Explore SEC and related filing metadata, where available.

20n Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about 20n Bio's valuation, stock price, and market status.

Is 20n Bio a public or private company?

20n Bio is a private company.

What is the current stock price of 20n Bio?

20n Bio is a private company with no public stock price. No recent secondary market data is available.

How much is 20n Bio worth (valuation)?

Valuation information for 20n Bio is not publicly available.

Can I buy 20n Bio stock?

20n Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was 20n Bio's last funding round?

20n Bio's most recent funding round was Seed on December 17, 2021.

Who are the main investors in 20n Bio?

Key investors in 20n Bio include Lanchi Ventures.

Will 20n Bio IPO soon?

No public IPO plans have been announced for 20n Bio.

How can I track 20n Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 20n Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMalvern, Pennsylvania
Employee Range3
Year Founded2021
Last FundingMay 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?